# Leslie Chong

Populaarseimad podcastide jaod
Uuendatud:

Leslie Chong, Imugene CEO

Imugene will forge ahead with a planned pivotal US trial for its blood cancer therapy Azer-cel, having recorded more ‘complete responses’ in its phase 1b study. See omnystudio.com/listener for privacy information.

Q+A: How this biotech CEO keeps the faith in a cancer cure

Biotech company Imugene reported its half-year results yesterday. It’s still loss-making, but sharply cutting costs and seeing what appear to be genuinely encouraging clinical results.Its lead cancer therapy, azer-cel, is showing strong response rates in difficult lymphoma cases, with some patients…

Q+A: How this biotech CEO keeps the faith in a cancer cure

Biotech company Imugene reported its half-year results yesterday. It’s still loss-making, but sharply cutting costs and seeing what appear to be genuinely encouraging clinical results.Its lead cancer therapy, azer-cel, is showing strong response rates in difficult lymphoma cases, with some patients…

PPC Management and Scaling (AI or not to AI) with Daniel Lai and Leslie Chong

GFA401. As an Amazon seller, we all know PPC is a make or break thing. Today we bring on co-founders of Scale Insights, Leslie and Daniel, to give us the thought process and overview of what we – as owners of our businesses – should do about PPC. For full show notes, check out GlobalFromAsia.com/pp…

Imugene azer-cel trial shows complete response

Imugene Ltd managing director and CEO Leslie Chong talked with Proactive about the first complete response reported in the concurrent Bruton Tyrosine Kinase inhibitor, or BTKi, cohort of the company’s ongoing Phase 1b azer-cel trial. Chong said the result was an important milestone for patients wi…

Imugene CEO on Phase 1b azer-cel data: second complete response

Imugene Ltd MD and CEO Leslie Chong talked with Proactive about the company reporting a second complete response in the concurrent Bruton Tyrosine Kinase inhibitor, or BTKi, cohort of its ongoing Phase 1b azer-cel trial. The latest response was recorded in the first mantle cell lymphoma, or MCL, p…